Verve Therapeutics (NASDAQ:VERV) Given “Market Perform” Rating at William Blair
William Blair reiterated their market perform rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. Several other equities analysts have also commented on the stock. Canaccord Genuity Group reiterated a “hold” rating and issued a $13.00 price target (down from $39.00) on shares of […]
William Blair reiterated their market perform rating on shares of Verve Therapeutics (NASDAQ:VERV – Free Report) in a research note issued to investors on Tuesday,Benzinga reports. Several other equities analysts have also commented on the stock. Canaccord Genuity Group reiterated a “hold” rating and issued a $13.00 price target (down from $39.00) on shares of […]
